Literature DB >> 12411586

Molecular validation of the modified Vienna classification of colorectal tumors.

Tamotsu Sugai1, Wataru Habano, Noriyuki Uesugi, Yu-Fei Jiao, Shin-ichi Nakamura, Kimihiko Sato, Toshimi Chiba, Motohiro Ishii.   

Abstract

Although the Vienna classification has been introduced to resolve discrepancies in histological diagnoses of colorectal tumors between Western and Japanese pathologists, practical applications of this classification scheme have been problematic because invasion of the lamina propria of tumor cells is often difficult to recognize. Therefore, the following refinements of the classification criteria are needed: category 3, low-grade adenoma/dysplasia; category 4, intramucosal borderline neoplasia; 4-a, high-grade adenoma/dysplasia; 4-b, well-differentiated adenocarcinoma; category 5, definite carcinoma; 5-a, intramucosal moderately-differentiated adenocarcinoma; and 5-b, submucosal carcinoma. We attempted to test whether molecular genetic alterations are related to the modified classification scheme and whether they may help to further categorize the various intramucosal neoplasia grades of colorectal tumors. Two-hundred-thirty-two colorectal tumors were examined using flow cytometric analysis of DNA content, polymerase chain reaction microsatellite assays, and single-strand conformational polymorphism assays to detect abnormalities of DNA content, chromosomal allelic loss, and Ki-ras and p53 gene mutations. Microsatellite instability (MSI) was also examined. Frequencies of genetic alterations and DNA aneuploid states increased with an increase in the grade assigned according to the modified Vienna classification. MSI was a rare event in colorectal adenomas and their frequency of MSI did not correlate with tumor grade. The combined genetic and DNA ploidy data support the conclusion that analysis of genetic alterations and DNA aneuploid states may help in appropriate categorization of colorectal tumors according to the modified Vienna scheme. In addition, MSI-positive tumors may represent a specific subtype of colorectal adenomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411586      PMCID: PMC1907360          DOI: 10.1016/s1525-1578(10)60703-9

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  30 in total

1.  Microsatellite instability in colorectal adenomas.

Authors:  W S Samowitz; M L Slattery
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

2.  A novel method for gene analysis of colorectal carcinomas using a crypt isolation technique.

Authors:  W Habano; T Sugai; S Nakamura; T Yoshida
Journal:  Lab Invest       Date:  1996-05       Impact factor: 5.662

3.  Ki-ras mutations in adenomas: a characteristic of cancer-bearing colorectal mucosa.

Authors:  R G Morris; L J Curtis; P Romanowski; J D Hardcastle; D A Jenkins; M Robinson; A H Wyllie; C C Bird
Journal:  J Pathol       Date:  1996-12       Impact factor: 7.996

4.  Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis.

Authors:  D T Leahy; R Salman; H Mulcahy; K Sheahan; D P O'Donoghue; N A Parfrey
Journal:  J Pathol       Date:  1996-12       Impact factor: 7.996

5.  Genetic instability in colorectal cancers.

Authors:  C Lengauer; K W Kinzler; B Vogelstein
Journal:  Nature       Date:  1997-04-10       Impact factor: 49.962

6.  Microsatellite instability in cancer of the proximal colon.

Authors:  S N Thibodeau; G Bren; D Schaid
Journal:  Science       Date:  1993-05-07       Impact factor: 47.728

7.  Application of the crypt-isolation technique to flow-cytometric analysis of DNA content in colorectal neoplasms.

Authors:  S Nakamura; J Goto; M Kitayama; I Kino
Journal:  Gastroenterology       Date:  1994-01       Impact factor: 22.682

8.  Incidence and recurrence rates of colorectal adenomas: a prospective study.

Authors:  A I Neugut; J S Jacobson; H Ahsan; J Santos; G C Garbowski; K A Forde; M R Treat; J Waye
Journal:  Gastroenterology       Date:  1995-02       Impact factor: 22.682

9.  p53 gene mutations in early colorectal carcinoma. De novo vs. adenoma-carcinoma sequence.

Authors:  H Hasegawa; M Ueda; K Furukawa; M Watanabe; T Teramoto; M Mukai; M Kitajima
Journal:  Int J Cancer       Date:  1995-02-20       Impact factor: 7.396

10.  Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients.

Authors:  R Kikuchi-Yanoshita; M Konishi; S Ito; M Seki; K Tanaka; Y Maeda; H Iino; M Fukayama; M Koike; T Mori
Journal:  Cancer Res       Date:  1992-07-15       Impact factor: 12.701

View more
  10 in total

1.  AMACR is associated with advanced pathologic risk factors in sporadic colorectal adenomas.

Authors:  Sotiris Lakis; Theodora Papamitsou; Constantina Panagiotopoulou; Rodoula Kotakidou; Vassiliki Kotoula
Journal:  World J Gastroenterol       Date:  2010-05-28       Impact factor: 5.742

2.  Analysis of molecular alterations in laterally spreading tumors of the colorectum.

Authors:  Tamotsu Sugai; Wataru Habano; Ryo Takagi; Hiroo Yamano; Makoto Eizuka; Noriyuki Arakawa; Yayoi Takahashi; Eiichiro Yamamoto; Keisuke Kawasaki; Syunichi Yanai; Kazuyuki Ishida; Hiromu Suzuki; Takayuki Matsumoto
Journal:  J Gastroenterol       Date:  2016-10-04       Impact factor: 7.527

3.  Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas.

Authors:  Tamotsu Sugai; Wataru Habano; Yu-Fei Jiao; Mitsunori Tsukahara; Yuichiro Takeda; Koki Otsuka; Shin-ichi Nakamura
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

4.  Invasive carcinomas may arise in colorectal adenomas with high-grade dysplasia and with carcinoma in situ.

Authors:  Carlos A Rubio; John G Delinassios
Journal:  Int J Clin Exp Med       Date:  2010-01-08

5.  Comprehensive molecular analysis based on somatic copy number alterations in intramucosal colorectal neoplasias and early invasive colorectal cancers.

Authors:  Tamotsu Sugai; Makoto Eizuka; Wataru Habano; Yasuko Fujita; Ayaka Sato; Ryo Sugimoto; Kouki Otsuka; Eiichiro Yamamoto; Takayuki Matsumoto; Hiromu Suzuki
Journal:  Oncotarget       Date:  2018-05-01

6.  Molecular alterations in colorectal adenomas and intramucosal adenocarcinomas defined by high-density single-nucleotide polymorphism arrays.

Authors:  Makoto Eizuka; Tamotsu Sugai; Wataru Habano; Noriyuki Uesugi; Yayoi Takahashi; Keisuke Kawasaki; Eiichiro Yamamoto; Hiromu Suzuki; Takayuki Matsumoto
Journal:  J Gastroenterol       Date:  2017-02-14       Impact factor: 7.527

7.  Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression.

Authors:  Nektaria Simiantonaki; Marios Taxeidis; Caren Jayasinghe; Ursula Kurzik-Dumke; Charles James Kirkpatrick
Journal:  BMC Cancer       Date:  2008-11-04       Impact factor: 4.430

8.  Molecular differences in the microsatellite stable phenotype between left-sided and right-sided colorectal cancer.

Authors:  Yayoi Takahashi; Tamotsu Sugai; Wataru Habano; Kazuyuki Ishida; Makoto Eizuka; Koki Otsuka; Akira Sasaki; Takanori Morikawa; Michiaki Unno; Hiromu Suzuki
Journal:  Int J Cancer       Date:  2016-12-01       Impact factor: 7.396

9.  Overexpression of xeroderma pigmentosum group C decreases the chemotherapeutic sensitivity of colorectal carcinoma cells to cisplatin.

Authors:  Yi Zhang; Jia Cao; Yanni Meng; Chunying Qu; Feng Shen; Leiming Xu
Journal:  Oncol Lett       Date:  2018-02-27       Impact factor: 2.967

10.  Analysis of the expression of cancer-associated fibroblast- and EMT-related proteins in submucosal invasive colorectal cancer.

Authors:  Tamotsu Sugai; Noriyuki Uesugi; Yuriko Kitada; Noriyuki Yamada; Mitsumasa Osakabe; Makoto Eizuka; Ryo Sugimoto; Yasuko Fujita; Keisuke Kawasaki; Eiichiro Yamamoto; Hiroo Yamano; Hiromu Suzuki; Takayuki Matsumoto
Journal:  J Cancer       Date:  2018-06-23       Impact factor: 4.207

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.